A pan-cancer analysis of the oncogenic and immunological roles of RGS5 in clear cell renal cell carcinomas based on in vitro experiment validation
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Regulator of G protein signaling 5 (RGS5) impacts cancer progression and immune response. High RGS5 expression correlates with better prognosis in renal cancer, highlighting its prognostic value.
Area Of Science
- Oncology
- Immunology
- Genetics
Background
- Regulator of G protein signaling 5 (RGS5) is a gene in tumor-resident pericytes involved in angiogenesis.
- Its roles in human cancer immunology and prognosis remain largely unexplored.
- This study provides a pan-cancer analysis of RGS5's carcinogenic and immunological functions.
Purpose Of The Study
- To investigate the oncogenic and immunological roles of RGS5 across various human cancers.
- To analyze the association of RGS5 with clinical features, tumor heterogeneity, and immune markers.
- To validate RGS5 expression and function in renal cancer.
Main Methods
- Utilized a standardized pan-cancer dataset for RGS5 analysis using R software.
- Conducted bioinformatics analysis to assess oncogenic and immunological roles.
- Performed clinical sample analysis and cellular experiments for renal cancer validation.
Main Results
- RGS5 is dysregulated in multiple malignancies and linked to patient prognosis.
- RGS5 expression correlates with tumor heterogeneity, stemness, and immune gene expression (MHC, immune activation, chemokines).
- High RGS5 expression predicts favorable prognosis in renal cancer, correlating with tumor-associated fibroblasts and affecting cancer cell behavior.
Conclusions
- RGS5 expression is significantly associated with clinical features in tumors.
- RGS5 plays a role in tumor progression and influences patient prognosis.
- RGS5 is a potential prognostic biomarker in various cancers, especially renal cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Guanine nucleotide exchange factors or GEF,
GTPase-activating proteins or GAPs, and
Guanine nucleotide-dissociation inhibitors or GDIs.
The GEF activates the GTPase by exchanging the bound-GDP with GTP. The...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...